CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 2018—Binding Site’s Immunologicals Group has added three recombinant Treponema pallidum antigens to its in vitro diagnostic product line: T. pallidum TpN-15, TpN-17, and TpN-47. The antigens are derived and sourced from E. coli via culture and then purified to a level of >95 percent and confirmed via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). They are available in a standard 0.2 mg filled vial, with larger, bulk configurations also available.
The company also added monoclonal antibodies to be used in research and IVD manufacturing applications involving hepatitis B surface antigen. Available monoclonals to HBsAg include those targeted toward HBsAg a 15.12.3.17; HBsAg a 25; HBsAg a S1.9; HBsAg a S2 A13; HBsAg a S2 B3; HBsAg a S3; HBsAg a S2 7A; HBsAg d AD1; and HBsAg y AY1. The antibodies are sourced from mice and manufactured to a purity level of >95 percent. They are packaged in a 1.0 mg filled vial with larger, bulk configurations also available.
Both products have been designed for use as an integral component within solid phase enzyme immunoassay test procedures, especially ELISAs, are preservative free, and have a shelf life of four years from the manufacturing date.
Binding Site, 800-453-9189
,